Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation: A societal perspective

Center for Health Sciences, SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025, USA.
Translational behavioral medicine 03/2011; 1(1):182-190. DOI: 10.1007/s13142-010-0009-8
Source: PubMed


There is a lack of evidence of the relative cost-effectiveness of proactive telephone counseling (PTC) and Web-based delivery of smoking cessation services in conjunction with pharmacotherapy. We calculated the differential cost-effectiveness of three behavioral smoking cessation modalities with varenicline treatment in a randomized trial of current smokers from a large health system. Eligible participants were randomized to one of three smoking cessation interventions: Web-based counseling (n=401), PTC (n=402), or combined PTC-Web counseling (n=399). All participants received a standard 12-week course of varenicline. The primary outcome was a 7-day point prevalent nonsmoking at the 6month follow-up. The Web intervention was the least expensive followed by the PTC and PTC-Web groups. Costs per additional 6-month nonsmoker and per additional lifetime quitter were $1,278 and $2,601 for Web, $1,472 and $2,995 for PTC, and $1,617 and $3,291 for PTC-Web. Cost per life-year (LY) and quality-adjusted life-year (QALY) saved were $1,148 and $1,136 for Web, $1,320 and $1,308 for PTC, and $1,450 and $1,437 for PTC-Web. Based on the cost per LY and QALY saved, these interventions are among the most cost-effective life-saving medical treatments. Web, PTC, and combined PTC-Web treatments were all highly cost-effective, with the Web treatment being marginally more cost-effective than the PTC or combined PTC-Web treatments.

Download full-text


Available from: Harold S Javitz
  • [Show abstract] [Hide abstract]
    ABSTRACT: The popularity of smoking cost-effectiveness (CE) analysis has grown rapidly. Differences in models and inputs mean results may not be comparable, and researchers may have to take them on trust because the methods are beyond their expertise and not always transparent. We describe a direct method and tables of results for researchers without specialist knowledge. We estimate the health benefit to an individual attributed to an intervention and compute tables of incremental cost-effectiveness ratios (ICERs) for interventions with varying incremental intervention effects and costs. Estimates of life years gained come from the longest epidemiological study. After discounting, adjustments are made for future cessation and relapse. The method is described in simple steps, and conservative inputs are used throughout. To look up an ICER, the user needs only to know the cost of the intervention per smoker and the effect as measured by the percentage of ex-smokers attributable to the intervention at either 6- or 12-month follow-up. Reanalysis of authoritative reports indicates that these ICERs are comparable to those from decision-analytic simulation models. Researchers can now obtain immediate estimates of the CE of interventions in general populations. The method is easily programmed in a spreadsheet. ICERs are from the payer perspective and exclude offset and societal costs. Interventions in subpopulations will require inputs specific to those populations. Readers who wish to include an adjustment for quality of life can easily do so. The tables might promote a standard approach, with interventions compared on a consistent and transparent basis.
    No preview · Article · Jan 2012 · Nicotine & Tobacco Research
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Internet and telephone treatments for smoking cessation can reach large numbers of smokers. There is little research on their costs and the impact of adherence on costs and effects. Objective To conduct an economic evaluation of The iQUITT Study, a randomised trial comparing Basic Internet, Enhanced Internet and Enhanced Internet plus telephone counselling (‘Phone’) at 3, 6, 12 and 18 months. Methods We used a payer perspective to evaluate the average and incremental cost per quitter of the three interventions using intention-to-treat analysis of 30-day single-point prevalence and multiple-point prevalence (MPP) abstinence rates. We also examined results based on adherence. Costs included commercial charges for each intervention. Discounting was not included given the short time horizon. Results Basic Internet had the lowest cost per quitter at all time points. In the analysis of incremental costs per additional quitter, Enhanced Internet+Phone was the most cost-effective using both single and MPP abstinence metrics. As adherence increased, the cost per quitter dropped across all arms. Costs per quitter were lowest among participants who used the ‘optimal’ level of each intervention, with an average cost per quitter at 3 months of US$7 for Basic Internet, US$164 for Enhanced Internet and US$346 for Enhanced Internet+Phone. Conclusions ‘Optimal’ adherence to internet and combined internet and telephone interventions yields the highest number of quitters at the lowest cost. Cost-effective means of ensuring adherence to such evidence-based programmes could maximise their population-level impact on smoking prevalence.
    Full-text · Article · Sep 2012 · Tobacco control
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since the previous version of this chapter was published (Swan, Hudmon, & Khroyan, 2003), many advances in the science of nicotine dependence have occurred. Although progress has been significant, nicotine dependence remains a substantial global problem, the solution of which will require sustained effort at the basic, genetic, environmental (individual and macro levels), and treatment levels. In this chapter, we highlight some of the most significant developments in the field of nicotine dependence research over the past 10 years. These highlights include an increased understanding of the role of individual variation in relevant neurochemical and metabolic pathways; the emergence of neuroimaging technologies that further specify areas in the brain that are influenced by environmental cues to smoke; a remarkable series of genetic epidemiological studies that have identified and replicated an association between variation in the CHRN A5-A3-B4 nicotinic gene cluster on chromosome 15 and nicotine dependence; a more complete picture of individual-level variables that influence risk for nicotine dependence, including gender, cultural, and psychiatric comorbidities; the recent development of new assessment tools for nicotine dependence; and a summary of empirically based behavioral and pharmacological treatments for nicotine dependence. We close the chapter with a review of the recent and current macroenvironmental contextual factors in which the science has taken place in the past decade, including the master settlement agreement between the states and the tobacco industry, the impact of continued public health efforts, evidence of the cost-effectiveness of treatment for nicotine dependence, implications of health care reform for tobacco use counseling, the emergence of potential reduced exposure products into the marketplace, and global efforts at tobacco control.Keywords:smoking cessation;clinical trials;tobacco control;risk factors;neurobiology
    No preview · Chapter · Sep 2012
Show more